Objective Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice. Methods This survey study was a retrospective observational study. A survey was used to collect clinical information on IPF cases that were treated with pirfenidone. This survey sheet came from physicians belonging to the Diffuse Lung Diseases Research Group. Results 502 patients at 22 institutes received pirfeidone treatment. Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1%); adverse effect was the most frequent reason for termination. The pirfenidone treatment lasted for two years or longer in 111 cases (22.1%). The mean change in the forced vital capacity (FVC) was -30±224 (SD) mL in the first year of treatment, -158±258 mL in the second year, and -201±367 mL in the third year. FVC improved by 10% or more in the first year in 10 (14.7%) of 68 cases, and showed a change of ±10% in 47 (69.1%) cases. It showed a change of ±10% in the second and third years in 61.7% and 62.5% of the patients, respectively. Conclusion The FVC improved in only a small percentage of patients who received pirfenidone treatment for a long period of time. However, a decrease in the FVC was prevented for three years in over half of the cases.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a disease with a poor prognosis (1, 2) . Lung fibrosis and irreversible honeycomb lungs characterize the disease. Pirfenidone, a compound with anti-fibrotic, anti-inflammatory, and antioxidant properties (3, 4) , is currently a drug approved for clinical use in the treatment of IPF. It was approved for production and sales for the first time ever in October 2008 after a Japanese phase III clinical study revealed that it suppressed a decrease in the vital capacity and progression-free survival rates (5) . The most recent Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCECD) study has confirmed pirfenidone's beneficial effects on disease progression in IPF patients (6) . However, the follow-up period of the clinical studies lasted only 52-72 weeks (5-7); long-term effects of pirfenidone use clinically have been poorly understood to date. Therefore, verifying pirfenidone's duration of efficacy and safety is an important Figure 1 . Flow chart of the data collection and analyses. From 22 institutes, information on 502 cases treated with pirfenidone was collected. Pirfenidone treatment was terminated in less than one year in 186 cases, while it was continued for two years or longer in 111 cases. Detailed pulmonary function test (PFT) information was available in only 68 cases; because data were missing due to the failure of periodical testing of the pulmonary function.
clinical issue.
The aims of this study were to investigate the experience of pirfenidone administration in clinical practice in a multicenter cooperative study, and clarify the reason for termination of the treatment within one year and the influence of pirfenidone on the change in the pulmonary function in cases treated for two years or longer.
Materials and Methods

Subjects and procedures
This survey study was a retrospective observational study. Fig. 1 shows the flowchart of the study. Clinical data on IPF patients treated with pirfenidone were collected with survey sheets from physicians belonging to the Diffuse Lung Diseases Research Group, and the data were then subjected to analysis. Physicians were asked to provide the total number of IPF patients who were treated with pirfenidone, the gender and age of the patients, and the clinical course of patients who stopped pirfenidone treatment less than one year after starting the treatment (due to adverse events, death, acute exacerbation, or concurrence of lung cancer) as well as that of patients who were continuously treated with pirfenidone for one year or longer in the survey sheet. They were also asked to provide clinical information on each patient who was treated continuously for two years or longer in another survey sheet. Clinical information on patients included symptoms [dyspnea Medical Research Council (MRC) scale], serum markers [Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D)], respiratory function tests, arterial blood gas analysis, exercise challenge tests, and time-course changes, in addition to age, gender, and details of treatment (including co-administered drugs). Symptoms (dyspnea MRC scale), serum markers (KL-6 and SP-D), respiratory function tests, arterial blood gas analysis, and exercise challenge tests were evaluated according to the treatment outcome evaluation criteria described in the official statement by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) (1). The time-course change in respiratory function was evaluated based on the data at one year before treatment, just before treatment, and 6, 12, 18, 24, 30, and 36 months after starting the treatment. The volume and rate of yearly changes in forced vital capacity (FVC) and DLco (diffusing capacity of the lung for carbon monoxide) were calculated as follows: ΔFVC (DLco) = FVC (DLco) at 12 months from first dosebaseline FVC (DLco), %ΔFVC (DLco) = [FVC at 12 months from first dose -baseline FVC (DLco)/baseline FVC (DLco)] ×100. Safety was evaluated based on the observed adverse effects. The Jichi Medical University Ethical Committee approved this study's design in advance.
Results
Pirfenidone treatment was administered in 502 IPF patients at 22 institutes ( Fig. 1) . Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1%); an adverse event was the most frequent reason for termination [77 cases (41.4%)], followed by IPF-related death including acute exacerbation in 60 (32.3%) cases. Pirfenidone treatment was continued for two years or longer in 111 cases (22.1%), and of these, detailed clinical information was available for 83 cases. Table 1 shows the background of those 83 patients. The patients' average age was Detailed pulmonary function data were available in 68 cases that were treated with pirfenidone for at least 2 years. Table 2 shows the yearly FVC and DLco changes. The aver- age change in FVC was -163 mL/year in 38 cases examined before treatment, while it was -30 mL (n=68) one year later, and -158 mL (n=47) and -201 mL (n=16) in the second and third years, respectively. Meanwhile, the average DLco change was -1.63 mL/min/mmHg/year in 25 cases examined before treatment, whereas the average change was -0.71 mL/ min/mmHg in the first year after pirfenidone treatment (n= 57), and -0.97 mL/min/mmHg (n=34) and -0.28 mL/min/ mmHg (n=12) in the second and third years, respectively (Table 2) . Therefore, the %ΔDLco in one year was less than 5% among patients who were treated for three years. Table 3 shows the distribution of cases in relation to yearly %ΔFVC and %ΔDLco. Compared with just before treatment, FVC improved by 10% or more in the first year in 10 (14.7%) of 68 cases, showed a change of ±10% in 47 cases (69.1%), and deteriorated by 10% or more in 11 cases (16.2%). It improved by 10% or more in the second and third years in 6.4% and 6.3% of the patients, respectively. In addition, it showed a change of ±10% in the second and third years in 61.7% and 62.5% of the patients, respectively. FVC improved by 5% or more in 12 (17.6%) of 68 cases, showed a change of less than ±5% in 31 cases (45.6%), and deteriorated by 5% or more in 25 cases (36.8%). In the 12 cases with 5% or more improvement in %ΔFVC, the average levels of clinical markers before treatment were: %VC, 77.4%; PaO2 at rest, 77.0 Torr; and lowest SpO2 during exercise, 84.8%. However, no significant differences in any of the clinical markers among the three groups were exhibited (data not shown). Compared with just before treatment, FVC showed a change of less than ±5% in 23 cases in the first year, and the FVC change was less than ±5% in the second year in 13 (56.5%) of 23 cases from whom data were collected. Among 16 cases that showed a deterioration in the FVC by 5% or more in the first year of treatment, FVC deteriorated by 5% or more thereafter in 9 (56.3%) of the 16 cases. Meanwhile, DLco improved by 15% or more in the first year in only 3 (5.3%) of 57 cases compared with just before treatment, showed a change of less than ±15% in 38 cases (66.7%), and deteriorated by 15% or more in 16 cases (28.1%). Fig. 2 shows the changes in %ΔFVC during 3 years in the three groups with FVC improved by 10% or more (the improved group), FVC change by ±10% (the stable group), and FVC deteriorated by 10% or more (the progressive group) at 1 year after the introduction of treatment. The time-course change in %ΔFVC varied among the cases, but FVC showed no deterioration for more than one year in the stable group and a deterioration in the FVC was prevented for three years in more than half of the cases.
Discussion
In this study, the effects of the long-term use of pirfenidone for IPF treatment were retrospectively examined using a clinical survey sheet. Twenty-two institutes contributed responses. This is the first report of a multi-center cooperative study on the experience of long-term pirfenidone administration in clinical practice in Japan. Pirfenidone treatment was continued for two years or longer in only 111 (22%) of the 502 cases, and it was difficult to continue treatment over a long period of time in about 80% of cases due to adverse effects and a deterioration of IPF including an acute exacerbation.
Among the individuals who had a follow-up appointment to examine their respiratory function, the yearly change in FVC was -163±230 mL before treatment, -30±224 mL in the first year of treatment, -158±258 mL in the second year, and -201±367 mL in the third year. The results of previous observational studies and clinical trials on IPF revealed that the average yearly reduction in VC is about 150-200 mL in IPF cases (1, 8) , whereas the average yearly reduction in FVC before treatment was 163 mL in the present study.
Therefore, the subject group in this study was considered appropriate for investigating the long-term use of pirfenidone. Yearly FVC decline in the first year of treatment was 30 mL, which was even less than that obtained in a phase III trial (80-90 mL) (5) . Recently, Okuda et al. reported that the mean change in FVC during the 6-month period prior to therapy initiation was -188 mL, which improved to -19 mL during the 6-month period after the therapy (9) . Meanwhile, in the present study, the yearly decline in FVC in the second and third years was 158 mL and 201 mL, respectively, and long-term pirfenidone treatment improved FVC in only a fraction of the cases. However, the time-course change in FVC varied among the individual cases, and a FVC change of ±10% was observed in 69.1% one year later and 61.7% two years later, which suggested the possibility that pirfenidone treatment prevents a deterioration in FVC over the long term and the treatment stabilized FVC in such cases.
In the present study, the FVC change was less than ±5% in the second year in 13 (56.5%) of 23 cases from whom data were collected, and the FVC deteriorated by 5% or more thereafter in 9 (56.3%) of 16 cases who showed a deterioration in the FVC by 5% or more in the first year of treatment. Schmidt et al. (10) demonstrated that a decline in the FVC predicted early mortality, but not any future declines in physiology. In the present study, there were not many cases in the long-term efficacy analysis, and the number of patients who underwent PFTs in the second year was low in this study. However, Taniguchi et al. (11) reported that about 70% of the cases in the group with no deterioration three months after pirfenidone treatment showed no aggravation 12 months later, and almost 90% of the cases with an aggravation in VC (reduction of 5% or more) after three months of treatment showed a persistent aggravation 12 months later. Although it is considered important to evaluate the long-term efficacy of pirfenidone from various perspectives, the present long-term efficacy study suggested that patients who showed a worsening of symptoms after pirfenidone treatment deteriorated even further.
Gastrointestinal symptoms and photosensitivity are critical adverse events associated with pirfenidone. It is important to balance efficacy and adverse events in the clinical use of pirfenidone (9, 12) . In the present study, the most common dose of pirfenidone administered for the longest period of time was 1,800 mg/day among cases that continued pirfenidone treatment for two years or longer. Gastrointestinal symptoms were observed in 32.6% of these cases. Valeyre et al. reported that the incidence of new-onset gastrointestinal and skin-related events declined markedly after the first 6 months and concluded that long-term treatment with pirfenidone was safe and generally well tolerated (13) . In our study, preventive medication for adverse effects, such as proton pump inhibitor, enabled long-term intake of pirfenidone, and its safety was thus reconfirmed.
There are some limitations associated with this study, such as some bias in the case selection. This study was a retrospective study that used a clinical survey sheet for data collection, and not all patients treated with pirfenidone in the participating institutes were examined prospectively with a clinical survey sheet. In addition, the physicians in charge provided responses, and adherence to pirfenidone intake could not be accurately confirmed. However, the participating institutes were specialized ones belonging to the Diffuse Lung Diseases Research Group, the project for refractory lung diseases was supported by a grant-in-aid from the Ministry of Health, Labour and Welfare in Japan, and responses were provided by physicians specializing in clinical practice on IPF. Thus, reliability was presumed to be high.
In conclusion, long-term treatment with pirfenidone improved the FVC in only a fraction of the cases, but it prevented a deterioration in the FVC over the long term in more than half of the cases without disease aggravation after the introduction of the treatment.
